Breast Cancer Treatment Tablets For Osteoporosis – Part 1 of 3
Breast Cancer Treatment Tablets For Osteoporosis. The bone upper zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a experimental study involving more than 3360 patients. The drug, long used to combat bone loss from osteoporosis, did not appear to prevent breast cancer from returning or to boost disease-free survival overall. British researchers presented the poor findings Thursday at the San Antonio Breast Cancer Symposium in Texas.
And “As a whole, the study is negative,” study author Dr Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday newsflash conference on the findings. “There is no overall difference in recurrence rates or survival rates between patients who got the bone dose and those who did not, except in older patients, defined as more than five years after menopause”.
That was a possible bright spot in the results. “In that population, there is a benefit”. The older women had a 27 percent enhancement in recurrence and a 29 percent improvement in overall survival over the five-year follow-up, compared to those who didn’t get the drug.
And “There was tremendous hope that this drug approach would be a major leap forward. There have been other trials that suggest this is the case”. In one sometime study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer. Other research has found that wholesome women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.